Cullinan Therapeutics (NASDAQ:CGEM) Coverage Initiated by Analysts at Stifel Nicolaus
Stifel Nicolaus began coverage on shares of Cullinan Therapeutics (NASDAQ:CGEM – Free Report) in a research note issued to investors on Wednesday, MarketBeat reports. The brokerage issued a buy rating and a $22.00 price target on the stock. Other research analysts also recently issued reports about the company. Morgan Stanley restated an “overweight” rating and […]
Stifel Nicolaus began coverage on shares of Cullinan Therapeutics (NASDAQ:CGEM – Free Report) in a research note issued to investors on Wednesday, MarketBeat reports. The brokerage issued a buy rating and a $22.00 price target on the stock. Other research analysts also recently issued reports about the company. Morgan Stanley restated an “overweight” rating and […]
